Correction to: Leukemia (2016) 30, 1701–1707; doi:10.1038/leu.2016.148
Following the publication of this article the authors noted that the IPSS risk assignment was incorrectly listed in the second paragraph of the Results section. The correct proportions of patients with intermediate-2-risk or high-risk MF should be 40 and 60%, respectively, not 60 and 40% as listed in the original.
The authors wish to apologize for any inconvenience caused.
The online version of the original article can be found at 10.1038/leu.2016.148
About this article
Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone
Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors
Medical Oncology (2018)
Blood Cancer Journal (2018)
An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms
Future Oncology (2018)